A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

por Shore, Neal, Mincik, Ivan, DeGuenther, Mark, Student, Vladimir, Jievaltas, Mindaugas, Patockova, Jitka, Simpson, Kelle, Hu, Chu-Hsuan, Huang, Shih-Tsung, Li, Yuhua, Lee, Yisheng, Chien, Ben, Mao, John
Publicado 2019

Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

por Gilling, Peter, Barber, Neil, Bidair, Mohamed, Anderson, Paul, Sutton, Mark, Aho, Tev, Kramolowsky, Eugene, Thomas, Andrew, Cowan, Barrett, Kaufman, Ronald P., Trainer, Andrew, Arther, Andrew, Badlani, Gopal, Plante, Mark, Desai, Mihir, Doumanian, Leo, Te, Alexis E., DeGuenther, Mark, Roehrborn, Claus
Publicado 2019

Self‐Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy

por Grizzle, William E., Kittles, Rick A., Rais‐Bahrami, Soroush, Shah, Ebony, Adams, George W., DeGuenther, Mark S., Kolettis, Peter N., Nix, Jeffrey W., Bryant, James E., Chinsky, Ravi, Kearns, James E., Dehimer, Kerry, Terrin, Norma, Chang, Hong, Gaston, Sandra M.
Publicado 2019